Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites

  • Research Article
  • Published:
Tumor Biology

Abstract

Management of gastric cancer with malignant ascites is a challenge, and limited data are available. We evaluated factors affecting survival for this condition to determine factors that predict survival outcome and to develop a rational treatment plan. We retrospectively studied 5,542 patients with gastric adenocarcinoma from January 2007 to December 2012. Among them, 347 patients (6.26 %) were associated with malignant ascites. The patients’ overall survival was compared among the different features. Three hundred forty-seven patients (153 females and 194 males; median age, 53 years) were enrolled, including 78 (22.5 %) young patients and 63 (18.1 %) elderly patients. One hundred forty-three (41.2 %) patients presented with malignant ascites at the initial diagnosis of gastric cancer, and 211 (60.8 %) received chemotherapy. After a median follow-up duration of 10.4 months, the median survival after the diagnosis of malignant ascites was 5.2 months (95 % CI, 4.8–5.6 months), and the 1-year survival rate was 16.1 %. An ECOG score greater than 2 (P < 0.001), the presence of ascites with the diagnosis of gastric cancer (P < 0.001), no chemotherapy (P < 0.001), an albumin level less than 30 g/L (P = 0.013), an ascites volume greater than 2,000 mL (P = 0.019), Helicobacter pylori infection (P = 0.010), and metastases to other organs (P = 0.037) were associated with poor prognosis, and they were all independent prognostic factors. The survival of gastric cancer patients with malignant ascites is relatively short, and ECOG score and the presence of ascites with the diagnosis of gastric cancer are the most important prognostic factors. Additionally, chemotherapy could improve the overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg. 1996;83(1):6–14. doi:10.1002/bjs.1800830104.

    Article  CAS  PubMed  Google Scholar 

  2. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):337–42. doi:10.1056/NEJM199402033300508.

    Article  CAS  PubMed  Google Scholar 

  3. Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733–7. doi:10.1001/archinte.161.22.2733.

    Article  CAS  PubMed  Google Scholar 

  4. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–9. doi:10.1093/annonc/mdl499.

    Article  CAS  PubMed  Google Scholar 

  5. Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23(8):1979–85. doi:10.1093/annonc/mds178.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589–97. doi:10.1016/j.ejca.2005.11.018.

    Article  PubMed  Google Scholar 

  7. Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1–9. doi:10.1007/ s10147 -012-0396-6.

    Article  PubMed  Google Scholar 

  8. Imamoto H, Oba K, Sakamoto J, Iishi H, Narahara H, Yumiba T, et al. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer. 2011;14(1):81–90.

    Article  CAS  PubMed  Google Scholar 

  9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  10. Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, et al. A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol. 2005;35(7):386–90. doi:10.1093/jjco/hyi109.

    Article  PubMed  Google Scholar 

  11. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol. 1996;22(3):237–9. doi:10.1016/S0748-7983(96)80009-6.

    Article  CAS  PubMed  Google Scholar 

  12. Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol. 1996;6(2):474–80.

    CAS  PubMed  Google Scholar 

  13. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27. doi:10.1007/s10120-012-0163-4.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67–70. doi:10.1093/annonc/mdp260.

    Article  CAS  PubMed  Google Scholar 

  15. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18(5):886–91. doi:10.1093/annonc/mdl501.

    Article  CAS  PubMed  Google Scholar 

  16. Mansour-Ghanaei F, Shafaghi A, Bagherzadeh AH, Fallah MS. Low gradient ascites: a seven-year course review. World J Gastroenterol. 2005;11(15):2337–9.

    PubMed  Google Scholar 

  17. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer. 1990;62(3):440–3. doi:10.1038/bjc.1990.314.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656–62. doi:10.1093/annonc/mds104.

    Article  CAS  PubMed  Google Scholar 

  19. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15(2):154–61. doi:10.1007/s10120-011-0091-8.

    Article  CAS  PubMed  Google Scholar 

  20. Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, Medina-Franco H. Clinicopathologic characteristics of gastric cancer in a young patient population. J Gastrointest Surg. 2004;8(3):240–4. doi:10.1016/j.gassur.2003.12.009.

    Article  PubMed  Google Scholar 

  21. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Choi WH, et al. Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol. 2008;15(5):1464–9. doi:10.1245/s10434-008-9809-1.

    Article  PubMed  Google Scholar 

  22. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Clinicopathological features of gastric carcinoma in younger and middle-aged patients: a comparative study. J Gastrointest Surg. 2006;10(7):1023–32. doi:10.1016/j.gassur. 2006. 03.001.

    Article  PubMed  Google Scholar 

  23. Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E. Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg. 2007;94(6):737–42. doi:10.1002/bjs.5600.

    Article  CAS  PubMed  Google Scholar 

  24. Warren JR, Marshall BJ. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1983;1(8336):1273–5.

    Google Scholar 

  25. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer. 2013;132(6):1272–6. doi:10.1002/ijc.27965.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392–7. doi:10.1016/S0140-6736(08)61159-9.

    Article  PubMed  Google Scholar 

  27. Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7(3):211–22. doi:10.1016/S1470-2045(06)70586-1.

    Article  PubMed  Google Scholar 

  28. Qiu HB, Zhang LY, Keshari RP, Wang GQ, Zhou ZW, Xu DZ, et al. Relationship between H. pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer. 2010;10:374. doi:10.1186/1471-2407-10-374.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Chen HY, Zhu BH, Zhang CH, Yang DJ, Peng JJ, Chen JH, et al. High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci. 2012;103(1):73–9. doi:10.1111/j.1349-7006.2011.02129.x.

    Article  CAS  PubMed  Google Scholar 

  30. Tamegai H, Kaiga T, Kochi M, Fujii M, Kanamori N, Mihara Y, et al. Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites. Cancer Chemother Pharmacol. 2013;71(3):727–31. doi:10.1007/s00280-012-2066-9.

    Article  CAS  PubMed  Google Scholar 

  31. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21. doi:10.1002/ijc.25423.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Gastrointestinal Department of Internal Medicine, The Fourth Affiliated Hospital of Nanchang University, Nanchang, 330006, China

    Nian Fang & Nong-Rong Wang

  2. The Third Department of Medical Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, 330029, China

    Hui-Qing Zhang, Bo He, Shan Lu & Yi-Ye Wan

  3. The Cytology Laboratory, Jiangxi Provincial Cancer Hospital, Nanchang, 330029, China

    Mei Xie

Authors
  1. Nian Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui-Qing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bo He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mei Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi-Ye Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nong-Rong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui-Qing Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fang, N., Zhang, HQ., He, B. et al. Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites. Tumor Biol. 35, 3261–3268 (2014). https://doi.org/10.1007/s13277-013-1426-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1426-3

Keywords

Search

Navigation